Diabetic Nephropathy
📧 Sign up to get email alerts when something new happens for Diabetic Nephropathy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-02-24FDA Approved: LISINOPRIL — Supplemental Application (Solco healthcare U.S., LLC)
The FDA approved a supplemental application for lisinopril from Solco Healthcare U.S., LLC.
-
FDA approval · 2016-02-23FDA Approved: CAPTOPRIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for CAPTOPRIL from Hikma Pharmaceuticals USA Inc.
-
FDA label_change · 2016-02-18FDA Approved: LISINOPRIL — Supplemental Application (Exelan Pharmaceuticals Inc.)
The FDA approved a supplemental application for lisinopril submitted by Exelan Pharmaceuticals Inc., typically resulting in labeling updates…
-
FDA approval · 2016-02-18FDA Approved: ENALAPRIL MALEATE — Supplemental Application (Northstar RxLLC)
FDA approved a supplemental application for Enalapril Maleate from Northstar RxLLC under an ANDA.
-
FDA approval · 2016-02-16FDA Approved: RAMIPRIL — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for Ramipril (generic ACE inhibitor) under ANDA 077626, enabling a generic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-02-10Clinical Trial Update: Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects [Phase 1, Phase 2]
The document reports the completion of a multiple-dose Phase 1/2 clinical trial of the anti-glycation agent GLY-230 in healthy subjects and …
-
FDA approval · 2016-02-05FDA Approved: AVAPRO — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for AVAPRO (irbesartan) from Sanofi-Aventis U.S. LLC.
-
FDA approval · 2015-12-07FDA Approved: IRBESARTAN — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original ANDA for Irbesartan, a generic angiotensin II receptor blocker. The approval allows Camber to …
-
FDA approval · 2015-11-17FDA Approved: IRBESARTAN — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approves a supplemental application for IRBESARTAN submitted by Solco Healthcare U.S., LLC.
-
CLINICAL_TRIALS trial_result · 2015-10-28Clinical Trial Update: Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes [Phase 2]
NephroGenex completed a Phase 2 safety and efficacy study of Pyridorin in patients with diabetic nephropathy (nephropathy due to type 2 diab…
-
FDA approval · 2015-10-26FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for losartan potassium from Alembic Pharmaceuticals Limited under the ANDA.
-
CLINICAL_TRIALS research · 2015-10-26Clinical Trial Update: Association of AGTR1 and ACACB Gene Polymorphism and Diabetic Nephropathy in Type 2 Diabetes
A completed clinical trial evaluating whether AGTR1 and ACACB gene polymorphisms are associated with diabetic nephropathy in individuals wit…
-
CLINICAL_TRIALS trial_result · 2015-10-21Clinical Trial Update: A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy [Phase 2]
This Phase 2 multi-center trial evaluated the efficacy and safety of a CCR2/5 receptor antagonist in adults with type 2 diabetes and overt n…
-
FDA approval · 2015-10-15FDA Approved: IRBESARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for IRBESARTAN (irbesartan), indicating an approved change to the generic p…
-
FDA approval · 2015-10-14FDA Approved: LOSARTAN POTASSIUM — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved the original application for a generic losartan potassium tablet by Unichem Pharmaceuticals (USA), Inc. for hypertension and re…
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: To Assess the Accuracy of the eZscan Study in the Screening for Diabetic Nephropathy
This document reports a completed clinical trial evaluating the accuracy of the eZscan screening method for diabetic nephropathy.
-
CLINICAL_TRIALS trial_result · 2015-09-16Clinical Trial Update: Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating MT-3995 at a low dose in patients with diabetic nephropathy, focusing on safety, tolerability, and ph…
-
CLINICAL_TRIALS trial_result · 2015-09-15Clinical Trial Update: Glucose in Dialysis Water in Diabetics With Chronic Renal Failure [Phase 4]
Phase 4 clinical trial evaluating glucose in dialysis water in diabetics with chronic kidney disease has completed.
-
CLINICAL_TRIALS trial_result · 2015-08-24Clinical Trial Update: Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy [NA]
This completed clinical trial from The Chinese University of Hong Kong evaluated whether disease-management strategies influence the develop…
-
CLINICAL_TRIALS trial_result · 2015-08-21Clinical Trial Update: The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy [Phase 2]
A Phase 2 clinical trial evaluating the effects of atorvastatin on the nitric oxide system in patients with Type 2 diabetes and nephropathy …
-
FDA approval · 2015-08-12FDA Approved: LOSARTAN POTASSIUM — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original generic application for losartan potassium, a generic version of the hypertension medication l…
-
CLINICAL_TRIALS trial_result · 2015-07-28Clinical Trial Update: Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients [Phase 4]
Phase 4 clinical trial evaluating whether saxagliptin improves microalbuminuria in patients with type 2 diabetes.
-
FDA label_change · 2015-07-27FDA Approved: DIOVAN — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for DIOVAN (valsartan) submitted by Novartis Pharmaceuticals Corporation, resulting in changes to th…
-
CLINICAL_TRIALS trial_result · 2015-07-24Clinical Trial Update: Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function. [NA]
A completed clinical trial evaluating the impact of exercise therapy on physical and vascular function in people with type 2 diabetes-relate…
-
CLINICAL_TRIALS trial_result · 2015-07-21Clinical Trial Update: The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy
Completed clinical trial assessing urine UbA52 as a diagnostic biomarker for diabetic nephropathy. The study was sponsored by Hebei Medical …